BioXcel Therapeutics EBIT

BioXcel Therapeutics (BTAI) currently reports a EBIT of $-63M as of March 2026. That compares with $-45M in the prior-year period — down 38.4% year over year. That is below the Healthcare sector average of $23B. Use the charts on this page to explore BioXcel Therapeutics's EBIT history and peer comparisons.

BioXcel Therapeutics's EBIT decreased from $-45M to $-63M — a 38.4% year-over-year decrease (period ending March 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

BioXcel Therapeutics's EBIT of $-63M is lower than the Healthcare sector average of $23B. That is roughly 100.3% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

BioXcel Therapeutics reported $-63M in EBIT as of March 2026. That compares with $-45M in the prior-year period — down 38.4% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current EBIT of $-63M, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is $23B. From there, open related valuation or income-statement pages for BioXcel Therapeutics, and consider following BTAI for alerts when major investors trade the stock.